Skip to main content
Erschienen in: Journal of Cardiovascular Magnetic Resonance 1/2018

Open Access 01.12.2018 | Research

Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction

verfasst von: Seung-Hoon Pi, Sung Mok Kim, Jin-Oh Choi, Eun Kyoung Kim, Sung-A Chang, Yeon Hyeon Choe, Sang-Chol Lee, Eun-Seok Jeon

Erschienen in: Journal of Cardiovascular Magnetic Resonance | Ausgabe 1/2018

Abstract

Background

It has been reported that left ventricular (LV) myocardial strain and late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) imaging have prognostic value in patients with heart failure (HF). However, previous studies included patients with various systolic functions. This study aimed to investigate the prognostic value of LV myocardial strain and LGE on CMR imaging in patients with idiopathic dilated cardiomyopathy (DCM) with reduced ejection fraction (EF < 40%).

Methods

From a prospectively followed cohort who underwent CMR between November 2008 and December 2015, subjects with LV EF < 40% and a diagnosis of idiopathic DCM were eligible for this study. The CMR images were analyzed for LV and right ventricular (RV) function, presence and extent of LGE, and LV myocardial strain. The primary outcome was a composite of all-cause death and heart transplantation. The secondary outcome was hospitalization for HF.

Results

A total of 172 patients were included, in whom mean LV EF was 23.7 ± 7.9% (EF 30–40% n = 47; EF < 30% n = 125). During a median follow-up of 47 months, the primary outcome occurred in 43 patients (16 heart transplantations, 29 all-cause deaths), and there were 41 hospitalizations for HF. Univariate Cox proportional hazard regression analysis showed that mean arterial pressure, serum sodium concentration, log of plasma NT-proBNP level, and presence of LGE (HR 2.277, 95% CI: 1.221–4.246) were significantly associated with the primary outcome. However, LV strain had no significant association (HR 1.048, 95% CI: 0.945–1.163). Multivariable analysis showed that presence of LGE (HR 4.73, 95% CI: 1.11–20.12) and serum sodium (HR 0.823, 95% CI: 0.762–0.887) were independently associated with the primary outcome.

Conclusions

LGE in CMR imaging was a good predictor of adverse outcomes for patients with idiopathic DCM and reduced EF. Identification of LGE could thus improve risk stratification in high-risk patients. LV strain had no significant prognostic value in patients with moderate to severe systolic dysfunction.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12968-018-0466-7) contains supplementary material, which is available to authorized users.
Seung-Hoon Pi and Sung Mok Kim contributed equally to this work.
Abkürzungen
ACE
Angiotensin converting enzyme inhibitor
ARB
Angiotensin receptor blocker
CMR
Cardiovascular magnetic resonance
DCM
Dilated cardiomyopathy
EDV
End diastolic volume
EF
Ejection fraction
ESV
End-systolic volume
GCS
Global circumferential strain
GLS
Global longitudinal strain
GRS
Global radial strain
HF
Heart failure
HR
Hazard ratio
LGE
Late gadolinium enhancement
LV
Left ventricle/Left ventricular
MAP
Mean arterial pressure
RV
Right ventricle/Right ventricular
SD
Standard deviation
sNA
Serum sodium

Background

Idiopathic dilated cardiomyopathy (DCM) accounts for a substantial proportion of heart failure (HF) cases [1, 2]. It is associated with significant morbidity and mortality due to HF and sudden cardiac death [35]. Although several factors in patients with HF [615] are associated with an adverse prognosis, risk stratification remains challenging. Therefore, better tools are needed for risk stratification in order to guide individualized treatment strategies and patient surveillance.
Cardiovascular magnetic resonance (CMR) imaging has become recognized as the gold standard for assessment of cardiac function and mass [16, 17], and it can be used to distinguish the etiology of HF [18, 19]. Additionally, it has been reported that the appearance of late gadolinium enhancement (LGE) [2023] and left ventricular (LV) myocardial strain in CMR imaging [24] have prognostic value in patients with non-ischemic DCM. However, those studies included patients with various systolic functions.
Therefore, we investigated the prognostic value of LV myocardial strain and LGE in the CMR images of patients with idiopathic DCM with reduced ejection fraction (EF).

Methods

Study population

From a prospectively followed cohort who underwent CMR at Samsung Medical Center, Seoul, Korea, between November 2008 and December 2015, subjects whose LV EF was less than 40% were eligible for this study (n = 441). Medical records were reviewed, and those from patients with an LV EF less than 40% who had been diagnosed previously with idiopathic DCM were evaluated. The diagnosis of DCM was made according to the criteria of the World Health Organization/International Society and Federation of Cardiology [25]. Patients had to exhibit dilatation and impaired contraction of the LV or both ventricles in the absence of valvular disease, hypertensive heart disease, and congenital abnormalities. The possibility of ischemic heart disease was excluded by invasive x-ray coronary angiography or non-invasive testing such as coronary computed tomography angiography (defined as ≥50% luminal stenosis) [24] or CMR itself (subendocardial or transmural pattern of LGE suggestive of previous myocardial infarction) [18], according to each physician’s clinical decision.
Of all potentially eligible patients (n = 441), pediatric patients (n = 20) and 154 patients with ischemic heart disease, constrictive pericarditis, tachycardia-induced cardiomyopathy, cardiomyopathy due to endocrine dysfunction, cardiomyopathy due to infection with the human immunodeficiency virus, stress induced cardiomyopathy, infiltrative myocardial disease, hypertensive heart disease, cardiomyopathy due to systemic autoimmune disease, alcoholic cardiomyopathy, cardiomyopathy related to chemotherapeutic agents, restrictive cardiomyopathy, significant organic valvular disease, or hypertrophic cardiomyopathy were excluded. Of 267 patients with a diagnosis of idiopathic DCM, we excluded 95 because their CMR images were inappropriate for strain measurement, resulting in a final sample size of 172 patients (Fig. 1). This study and all of its analyses were approved by the Institutional Review Board of Samsung Medical Center which waived written informed consent.

CMR image acquisition

All subjects underwent CMR in a 1.5 T scanner (Magnetom Avanto, Syngo MR B17 version; Siemens Healthineers, Erlangen, Germany) with a 32-channel phased-array receiver coil. CMR scans consisted of localizing images (axial, coronal, and sagittal), cine scans, and LGE scans. After localization, cine images of the LV were acquired using a balanced steady-state free-precession sequence in the 4-, 3-, and 2-chamber and short axis views to obtain contiguous slices that included the entire LV, with a 6-mm slice thickness and 4-mm intersection gaps. At each level, cine images were composed of 30 phases per cardiac cycle. Cine images were obtained during multiple breath-holds. LGE imaging was acquired using a phase-sensitive inversion recovery technique 10 min after injection of 0.2 mmol/kg gadobutrol (Gadovist; Bayer Healthcare, Berlin, Germany) at a rate of 3 ml/sec, followed by a 30-ml saline flush. Contiguous short-axis image acquisition of 10–12 slices was used, with 6 mm thickness and a 4-mm interslice gap. Inversion delay times were typically 280–360 msec.

LV myocardial strain analysis

CMR tissue tracking analyses were performed using commercially available software (cvi42 version 5, Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada). Two-, three-, and four-chamber and short axis images were uploaded into the software, which reconstructs a 3D model that we used to analyze 2D-radial, circumferential, and longitudinal LV strain. The preferred images were loaded into the analysis/viewer frame of the software and analyzed in random order by two investigators (SHP with 1 year and JWH with 3 years of CMR experience) who were independently blinded to the clinical findings. Tissue tracking analysis was manually performed by drawing the endo- and epicardial surfaces in end-diastolic phase (reference phase) using short axis stacked slices (Fig. 2). A short axis reference point was manually delineated at the right ventricle (RV) upper and lower septal insertion of the LV for regional and global analysis of strain and the generation of polar map views. Next, the software automatically drew the contour and traced its myocardium voxel points throughout the remainder of the cardiac cycle. The algorithm determined and depicted the left borders of the LV myocardium in the following phases of a cardiac cycle based on the endo- and epicardial contours of the reference phase. The software automatically performed 2D strain analyses of all slices.
The routine cine images of 172 patients included for strain analysis consist of 30 images per cardiac cycle. Those images were acquired using retrospective (electrocardiogram (ECG)-gated, multi-breathhold technique. The patients excluded from the analyses for strain underwent different scan technique using single-breathhold method for obtaining cine images because of arrhythmia or lack of breath-hold. Because of this, the number of image frames was variable (10~ 24 images), so the temporal resolution was also different and we could not perform the analysis of LV strain.

LGE measurement

The presence and extent of LGE were evaluated by one observer experienced in LGE-CMR, who was blinded to clinical data and outcomes. For quantification of fibrosis, LGE was defined as areas with a signal intensity >6SD [26, 27] above the mean signal intensity of remote myocardium in the same short-axis slice using commercial software (CAAS MRV version 1.0, Pie Medical Imaging B.V., Maastricht, The Netherlands). Areas are expressed as mass and percentage of myocardial mass.

Follow-up and endpoints

All patients were followed by medical record review. Vital status was cross-checked in all of the patients using National Insurance data from the Korean government, which contain unique identifiers for the patients [28]. The median follow-up duration was 1400 days (Q1–Q3: 770 to 2210 days). The primary outcome was a composite of all-cause death and heart transplantation. The secondary outcome was first hospitalization due to HF.

Statistical analysis

Categorical variables are presented as numbers and relative frequencies (percentages), and continuous variables as means and standard deviations or medians with interquartile ranges (Q1–Q3), according to their distribution, which was checked using the Kolmogorov-Smirnov test. Categorical variables were compared using chi-square tests, and continuous variables were compared using Student’s t-test or analysis of variance. Cumulative events rates were calculated based on Kaplan-Meier censoring estimates, and the log-rank test was used to compare survival curves. We proceeded with multiple Cox regression model to understand the variability in time to event in the two primary endpoints. Based on univariate analysis, all demographic or clinical variables with p-values < 0.2 were initially considered to enter the model. Then, we eliminated insignificant variables (p > 0.05) one by one to obtain a robust and parsimonious model for prediction. We verified the model assumption of proportional hazards via Schoenfeld residuals. When the assumption fails, we attempted accommodating time-dependent covariates and stratified analyses. As a measure of goodness of the prediction model, we obtained the Harrel’s c-index. Pearson correlation coefficient was calculated to assess the correlation between LVEF and LV myocardial strains. Inter- and intra-observer variabilities for strain values were assessed by the repeated analysis of 30 randomly selected patients. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, North Carolina, USA), and SPSS (version 19.0, International Business Machines, Armonk, New York, USA). P-values < 0.05 (2-sided) were considered statistically significant.

Results

Baseline characteristics

The baseline clinical characteristics and CMR variables of all 172 patients are summarized in Tables 1 and 2. Also these data of those who were excluded from and included in the strain analysis was presented in the Additional file 1: Tables S1 and S2. There was no significant difference between 95 excluded and 172 included patients except gender, presence of LBBB, LV myocardial mass. There was no difference in the presence of LGE between the two groups. Mean LV EF of the study subjects was 23.7 ± 7.9% (EF 30–40% n = 47; EF < 30% n = 125) and LGE was observed in 66 (38.2%) patients. The Pearson correlation coefficients between LV EF and GLS, GCS, and GRS were − 0.733 (P < 0.01), − 0.780 (P < 0.01), and 0.739 (P < 0.01).
Table 1
Baseline characteristics and CMR parameters for patients with and without the primary outcome
Parameters
All patients (n = 172)
Patients without the primary outcome (n = 129)
Patients with the primary outcome (n = 43)
P value
Age (years)
56.4 ± 14.3
57.0 ± 14.6
54.8 ± 13.5
0.398
Male gender, n (%)
116 (67.4)
85 (65.9)
31 (72.1)
0.452
Mean arterial pressure (mmHg)
84 ± 13
86 ± 13
80 ± 12
0.015
Hypertension, n (%)
58 (33.7)
44 (34.1)
14 (32.6)
0.852
Diabetes mellitus, n (%)
36 (20.9)
25 (19.4)
11 (25.6)
0.387
Dyslipidemia, n (%)
11 (6.4)
8 (6.2)
3 (7.0)
0.857
Current smoker, n (%)
49 (28.5)
37 (28.7)
12 (27.9)
0.734
Chronic kidney diseasea, n (%)
31 (18.0)
21 (16.3)
10 (23.3)
0.303
Previous CVA, n (%)
4 (2.3)
1 (0.8)
3 (7.0)
0.049
Body mass index (kg/m2)
24.0 ± 4.5
24.2 ± 4.5
23.5 ± 4.4
0.347
ECG at baseline
    
 Heart rate (bpm)
83 ± 20
84 ± 19
83 ± 22
0.883
 Left bundle-branch block, n (%)
31 (18.0)
23 (17.8)
8 (19.0)
0.859
 QRS duration (ms)
113 ± 29
112 ± 30
117 ± 29
0.305
Laboratory data
    
 Serum creatinine (mg/dl)
0.97 ± 0.27
0.96 ± 0.25
1.01 ± 0.31
0.247
 Na (mmol/l)
139.6 ± 3.3
140.2 ± 2.8
137.6 ± 3.8
< 0.001
 ln(NT-proBNP) (pg/ml)
7.22 ± 1.27
7.08 ± 1.29
7.60 ± 1.16
0.022
Cardiac medications
    
 Beta-blockers, n (%)
120 (69.8)
87 (67.4)
33 (76.7)
0.250
 ACE-inhibitors/ARB, n(%)
134 (77.9)
104 (80.6)
39 (90.7)
0.126
 Spironolactone, n (%)
101 (58.7)
74 (57.4)
27 (62.8)
0.531
 Diuretics, n (%)
125 (72.7)
93 (72.1)
32 (74.4)
0.767
 Digoxin, n (%)
33 (19.2)
21 (16.3)
12 (27.9)
0.094
Primary outcome: all-cause death, heart transplantation during follow-up. Values are mean ± SD, n(%)
aChronic kidney disease was defined as eGFR < 60 ml/min/1.73m2, calculated using the 4-component MDRD study equation
Abbreviations: ACE angiotensin-converting-enzyme, ARB angiotensin II receptor blockers, BNP B-type natriuretic peptide, CVA cerebrovascular accident ECG electrocardiography
Table 2
Baseline standard CMR-data and myocardial deformation parameters of patients with and without the primary outcome
Parameters
All patients (n = 172)
Patients without the primary outcome (n = 129)
Patients with the primary outcome (n = 43)
P value
LV EF (%)
23.7 ± 7.9
23.6 ± 8.0
24.1 ± 7.5
0.675
LV EDV (ml)
284.3 ± 91.4
279.2 ± 81.5
299.9 ± 116.0
0.199
LV ESV (ml)
219.9 ± 85.7
215.5 ± 76.4
233.2 ± 109.0
0.242
Cardiac output (L/min)
5.04 ± 1.53
4.95 ± 1.51
5.32 ± 1.57
0.166
Cardiac index (L/min/m2)
2.95 ± 0.84
2.89 ± 0.82
3.12 ± 0.88
0.114
RV EF (%)
41.2 ± 17.0
42.3 ± 18.0
37.7 ± 12.8
0.129
RV EDV (ml)
145.6 ± 60.7
140.7 ± 56.3
160.3 ± 70.9
0.066
RV ESV (ml)
91.6 ± 56.7
87.1 ± 53.8
105.1 ± 63.3
0.071
RV cardiac output (L/min)
4.21 ± 1.33
4.14 ± 1.23
4.43 ± 1.59
0.227
Presence of LGE, n (%)
66 (38.4)
42 (33.1)
24 (58.5)
0.004
Myocardial mass (g)
142.2 ± 41.1
144.1 ± 43.6
136.5 ± 31.9
0.232
Quantitative LGE mass (g)
6.8 ± 14.5
5.6 ± 13.3
10.6 ± 17.2
0.093
LGE mass/LV myocardial mass (%)
4.7 ± 9.5
3.8 ± 8.6
7.4 ± 11.5
0.073
Global radial strain (%)
12.3 ± 5.6
12.5 ± 5.6
11.9 ± 5.8
0.563
Global circumferential strain (%)
−7.3 ± 3.1
−7.3 ± 3.1
−7.2 ± 3.2
0.869
Global longitudinal strain (%)
−7.1 ± 2.9
−7.2 ± 2.9
−6.9 ± 2.7
0.613
Primary outcome: all-cause death, heart transplantation. Values are mean ± SD, n(%)
Abbreviations: CMR cardiovascular magnetic resonance, EDV end-diastolic volume, EF, ejection fraction, ESV end-systolic volume, LGE late gadolinium enhancement, LV left ventricle, RV right ventricle

Outcomes

During the follow-up period, the primary outcome occurred in 43 patients (16 heart transplantations, 29 all-cause deaths), and there were 41 hospitalizations for HF. Between patients with and without the primary outcome, significant differences were observed in terms of mean arterial pressure (MAP), serum sodium (sNa), log transformed NT-proBNP [ln(NT-proBNP)], and presence of LGE. Regarding LV myocardial strain, none of the systolic strain parameters differed significantly between groups.

Survival analysis

By univariate analysis, the following clinical parameters were predictors of the primary outcome: presence of LGE, MAP, history of cerebrovascular accident, Na, ln(NT-proBNP), RV end-diastolic volume (EDV), and RV end-systolic volume (ESV). The presence of LGE, MAP, sNa, ln(NT-proBNP), LV ESV, RV EF, RV ESV, and LV mass were all predictors of the secondary outcome. LV myocardial strain had no significant association with either the primary or secondary outcome (Table 3). Kaplan-Meier curves for the clinical outcomes according to presence of LGE and global longitudinal strain (GLS) are shown in Fig. 3. In Fig. 3c, d, patients were divided into two groups by the median GLS of the total population (− 6.8%).
Table 3
Univariate analysis of primary and secondary outcomes
 
Primary outcome
Secondary outcome
HR
95% CI
P value
HR
95% CI
P value
Age (years)
0.993
0.973–1.013
0.487
0.991
0.970–1.011
0.373
Male gender
1.350
0.693–2.631
0.378
0.726
0.388–1.361
0.318
Mean arterial pressure (mmHg)
0.971
0.945–0.997
0.028
0.959
0.931–0.986
0.004
Hypertension
1.257
0.663–2.384
0.483
0.896
0.449–1.789
0.756
Diabetes mellitus
1.417
0.712–2.818
0.321
1.387
0.679–2.833
0.369
Dyslipidemia
1.521
0.469–4.936
0.485
0.945
0.228–3.917
0.938
Current smoker
0.978
0.474–2.017
0.951
0.853
0.403–1.807
0.678
Chronic kidney diseasea
1.660
0.813–3.389
0.164
1.709
0.837–3.492
0.141
Previous CVA
3.501
1.079–11.362
0.037
2.265
0.545–9.418
0.261
Body mass index, kg/m2
0.960
0.888–1.037
0.298
0.936
0.858–1.021
0.134
ECG at baseline
      
 Heart rate (bpm)
1.000
0.984–1.015
0.972
1.013
0.997–1.029
0.109
 Left bundle-branch block
1.122
0.519–2.426
0.770
1.580
0.774–3.224
0.209
 QRS duration (ms)
1.005
0.995–1.015
0.353
1.003
0.993–1.013
0.598
Laboratory data
      
 Serum creatinine (mg/dl)
2.249
0.784–6.455
0.132
0.950
0.271–3.334
0.950
 Na (mmol/l)
0.810
0.751–0.875
< 0.001
0.860
0.794–0.931
< 0.001
 ln(NT-proBNP) (pg/ml)
1.376
1.083–1.748
0.009
1.519
1.190–1.939
0.001
Cardiac medications
      
 Beta-blockers
1.148
0.564–2.334
0.704
0.767
0.396–1.486
0.432
 ACE-inhibitors/ARB
1.492
0.531–4.192
0.447
2.171
0.669–7.050
0.197
 Spironolactone
1.100
0.588–2.056
0.766
1.380
0.724–2.632
0.328
 Diuretics
0.921
0.463–1.832
0.814
1.732
0.767–3.914
0.187
 Digoxin
1.658
0.847–3.242
0.140
1.662
0.847–3.258
0.140
LV EF (%)
1.006
0.969–1.044
0.759
0.970
0.933–1.009
0.132
LV EDV (ml)
1.003
1.000–1.006
0.093
1.003
1.000–1.006
0.090
LV ESV (ml)
1.003
0.999–1.006
0.108
1.004
1.000–1.007
0.041
Cardiac output (L/min)
1.092
0.908–1.314
0.349
0.961
0.784–1.177
0.699
Cardiac index (L/min/m2)
1.228
0.868–1.738
0.245
1.024
0.708–1.481
0.901
RV EF (%)
0.984
0.964–1.005
0.124
0.976
0.955–0.998
0.033
RV EDV (ml)
1.005
1.000–1.009
0.041
1.004
0.999–1.009
0.080
RV ESV (ml)
1.005
1.000–1.009
0.049
1.005
1.000–1.010
0.045
RV stroke volume (ml)
1.007
0.991–1.024
0.376
0.995
0.977–1.012
0.556
RV cardiac output (L/min)
1.122
0.894–1.407
0.320
0.962
0.759–1.220
0.751
Presence of LGE
2.277
1.221–4.246
0.010
2.023
1.066–3.839
0.031
Myocardial mass (g)
0.997
0.990–1.005
0.510
0.987
0.978–0.997
0.008
Quantitative LGE mass (g)
1.014
0.998–1.031
0.086
1.009
0.990–1.028
0.370
LGE mass/LV myocardial mass (%)
1.024
0.998–1.051
0.068
1.018
0.989–1.047
0.232
Global radial strain (%)
0.974
0.921–1.030
0.363
0.955
0.901–1.013
0.129
Global circumferential strain (%)
1.030
0.934–1.136
0.554
1.062
0.963–1.172
0.229
Global longitudinal strain (%)
1.048
0.945–1.163
0.375
1.066
0.955–1.191
0.254
aChronic kidney disease was defined as eGFR < 60 ml/min/1.73m2, calculated using the 4-component MDRD study equation
Abbreviations: ACE angiotensin-converting-enzyme, ARB angiotensin II receptor blockers, BNP B-type natriuretic peptide, CI confidence interval, CVA cerebrovascular accident, ECG, electrocardiography, EDV end-diastolic volume, EF, ejection fraction, ESV, end-systolic volume, HR, hazard ratio, LGE late gadolinium enhancement, LV, left ventricle, RV, right ventricle
Multivariable analysis showed that presence of LGE and sNa were independently associated with the primary outcome and presence of LGE, sNa, myocardial mass and ln(NT-proBNP) were independent predictors for secondary outcome. However, the effect of LGE did not satisfy the proportional hazard assumption for the primary outcome, and as stated in the Statistical methods section, we accommodate the LGE effects as time-dependent. The best model indicated that the effect of LGE was significant and dramatically apparent after about 6 months (Table 4).
Table 4
Multivariable proportional-hazard model of primary and secondary outcomes
 
Primary outcome a
Secondary outcome
HR
95% CI
P value
HR
95% CI
P value
Na (mmol/l)
0.821
0.761–0.885
< 0.001
0.896
0.817–0.982
0.019
Presence of LGE
4.729
1.111–20.121
0.0355
2.358
1.229–4.523
0.010
Myocardial mass
   
0.986
0.975–0.996
0.009
lnNT-proBNP
   
1.352
1.031–1.771
0.029
aBased on a multivariable Cox model with time-dependent covariates at 6 months. Before 6 months, the HR was 0.71 (p-value = 0.58, 95% CI: 0.206, 2.415), while after 6 months, the HR is as given in the Table
The Harrell’s c-index of multivariable Cox proportional hazards model were 0.727 (95% CI: 0.616 to 0.838) and 0.744 (95% CI: 0.648 to 0.839) for primary and secondary outcomes, respectively
Abbreviations: NT-proBNP, N-terminal pro-B-type natriuretic peptide; CI confidence interval, HR hazard ratio, LGE late gadolinium enhancement

Reliability

Intra- and inter-observer reliability values were excellent. Intra- and inter-observer intraclass correlation coefficients were 0.993 (95% CI: 0.985–0.997) and 0.944 (95% CI: 0.875–0.975), respectively, for GLS; 0.993 (95% CI: 0.985–0.997) and 0.962 (95% CI: 0.915–0.983), respectively, for global circumferential strain (GCS); and 0.986 (95% CI: 0.971–0.993) and 0.955 (95% CI: 0.899–0.980), respectively, for global radial strain (GRS).

Discussion

In this study, we evaluated the clinical outcomes of idiopathic DCM patients with moderate to severe LV systolic dysfunction according to CMR-derived LV strain and LGE. Our major finding was that LV strain had no significant prognostic value in these high-risk patients while the presence of LGE was a significant predictor of adverse outcomes.

Differential prognosis according to LV strain

To the best of our knowledge, a study published by Buss et al. has been the only other study that evaluated the prognostic value of CMR-derived LV strain in the DCM population [24]. In contrast to our study, they found that CMR-derived LV longitudinal strain was an independent predictor of survival in DCM that offered incremental information for risk stratification beyond clinical parameters, biomarkers, and standard CMR. However, they included patients with various systolic functions, and the LV EF of their study population was 36.1 ± 13.8%, much higher than that in our study (23.7 ± 7.9%).
LV myocardial strain is inevitably related to LV EF, and it has been reported that LV EF is determined by global myocardial strain and myocardial thickness [29]. In our study, the Pearson correlation coefficients between LV EF and GLS, GCS, and GRS were − 0.733 (P < 0.01), − 0.780 (P < 0.01), and 0.739 (P < 0.01), respectively. LV EF was not associated with the outcomes in our study, as expected because all of our study patients had severely depressed LV EF. Likewise, it is not surprising that LV strain could not predict adverse outcomes because it is so closely related to LV EF.

Differential prognosis according to LGE

Regarding the differential clinical outcomes according to LGE, previous studies have well demonstrated this correlation in patients with DCM. It has been reported that presence of LGE was associated with adverse clinical outcomes such as cardiovascular death, hospitalization due to HF, and sudden death [2023, 30]. This study showed results similar to those of previous studies: the presence of LGE was the strong independent predictor for adverse outcomes. We also considered the quantitative extent of LGE, but the extent of LGE was not significantly related to clinical outcomes. The presence of LGE might thus be more important than the extent of LGE when predicting adverse outcomes.

Limitations

This study has some important limitations. First, there are inherent limitations in non-randomized comparisons, such as allocation bias, uneven distribution of risk factors, and the possibility of unmeasured confounders. Second, data regarding the cause of death such as cardiovascular death including pump failure and sudden cardiac death was not available. Third, the follow-up duration varied by individual patient. Next limitation was that those with several forms of reversible cardiomyopathies such as tachycardia induced cardiomyopathy or hypertensive heart failure were excluded. Furthermore, many patients were excluded from the analysis of LV strain. Since this might have resulted in selection bias, so the findings of our study would not be generalizable to the entire HF with reduced EF population. However, there was no difference in the presence of LGE which was one of main CMR variable between those who were included in the strain analysis and excluded patients. Thus the overall finding might be not affected. Lastly, HF management was not controlled; thus, our conclusions should not be extrapolated to all patients with idiopathic DCM. A further study with a prospective and multicenter design is required.

Conclusions

In idiopathic DCM patients with reduced EF, CMR LGE is a good predictor of adverse outcomes. LV strain, however, had no significant prognostic value in patients with moderate to severe systolic dysfunction. As our study was analyzed retrospectively and selection bias could not be excluded, further studies with prospective design are warranted to support our findings.

Acknowledgements

The authors thank Prof. Keumhee Carriere (Research Professor, Samsung Medical Center, and Professor of Statistics, Department of Mathematical and Statistical Sciences, University of Alberta, Canada) for providing statistical consultation.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Ethical approval was obtained by the local Institutional Review Board of Samsung Medical Center (IRB File No. SMC 2017–01-104). All study subjects agreed to provide information for CMR cohort registry and written informed consent for this study was waived from our Institutional Review Board.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–84.CrossRefPubMed Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–84.CrossRefPubMed
2.
Zurück zum Zitat Choi DJ, Han S, Jeon ES, Cho MC, Kim JJ, Yoo BS, et al. Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the korean heart failure registry. Korean Circ J. 2011;41:363–71.CrossRefPubMedPubMedCentral Choi DJ, Han S, Jeon ES, Cho MC, Kim JJ, Yoo BS, et al. Characteristics, outcomes and predictors of long-term mortality for patients hospitalized for acute heart failure: a report from the korean heart failure registry. Korean Circ J. 2011;41:363–71.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47:525–31.CrossRefPubMed Fuster V, Gersh BJ, Giuliani ER, Tajik AJ, Brandenburg RO, Frye RL. The natural history of idiopathic dilated cardiomyopathy. Am J Cardiol. 1981;47:525–31.CrossRefPubMed
4.
Zurück zum Zitat Juilliere Y, Danchin N, Briancon S, Khalife K, Ethevenot G, Balaud A, et al. Dilated cardiomyopathy: long-term follow-up and predictors of survival. Int J Cardiol. 1988;21:269–77.CrossRefPubMed Juilliere Y, Danchin N, Briancon S, Khalife K, Ethevenot G, Balaud A, et al. Dilated cardiomyopathy: long-term follow-up and predictors of survival. Int J Cardiol. 1988;21:269–77.CrossRefPubMed
5.
Zurück zum Zitat Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113:1807–16.CrossRefPubMed Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association scientific statement from the council on clinical cardiology, heart failure and transplantation committee; quality of care and outcomes research and functional genomics and translational biology interdisciplinary working groups; and council on epidemiology and prevention. Circulation. 2006;113:1807–16.CrossRefPubMed
6.
Zurück zum Zitat Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003;42:736–42.CrossRefPubMed Curtis JP, Sokol SI, Wang Y, Rathore SS, Ko DT, Jadbabaie F, et al. The association of left ventricular ejection fraction, mortality, and cause of death in stable outpatients with heart failure. J Am Coll Cardiol. 2003;42:736–42.CrossRefPubMed
7.
Zurück zum Zitat Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008;299:2656–66.CrossRefPubMed Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008;299:2656–66.CrossRefPubMed
8.
Zurück zum Zitat Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation. 2003;107:1278–83.CrossRefPubMed Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the valsartan heart failure trial (Val-HeFT). Circulation. 2003;107:1278–83.CrossRefPubMed
9.
Zurück zum Zitat Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116:249–57.CrossRefPubMed Miller WL, Hartman KA, Burritt MF, Grill DE, Rodeheffer RJ, Burnett JC Jr, et al. Serial biomarker measurements in ambulatory patients with chronic heart failure: the importance of change over time. Circulation. 2007;116:249–57.CrossRefPubMed
10.
Zurück zum Zitat Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRefPubMed Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302.CrossRefPubMed
11.
Zurück zum Zitat Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91.CrossRefPubMed Yusuf S, Pitt B, Davis CE, Hood WB Jr, Cohn JN. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992;327:685–91.CrossRefPubMed
12.
Zurück zum Zitat Grayburn PA, Appleton CP, DeMaria AN, Greenberg B, Lowes B, Oh J, et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure. the Beta-blocker Evaluation of Survival Trial (BEST) J Am Coll Cardiol. 2005;45:1064–71.PubMed Grayburn PA, Appleton CP, DeMaria AN, Greenberg B, Lowes B, Oh J, et al. Echocardiographic predictors of morbidity and mortality in patients with advanced heart failure. the Beta-blocker Evaluation of Survival Trial (BEST) J Am Coll Cardiol. 2005;45:1064–71.PubMed
13.
Zurück zum Zitat Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257–67.CrossRefPubMed Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation. 1986;73:257–67.CrossRefPubMed
14.
Zurück zum Zitat Adams KF Jr, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996;28:1781–8.CrossRefPubMed Adams KF Jr, Dunlap SH, Sueta CA, Clarke SW, Patterson JH, Blauwet MB, et al. Relation between gender, etiology and survival in patients with symptomatic heart failure. J Am Coll Cardiol. 1996;28:1781–8.CrossRefPubMed
15.
Zurück zum Zitat Oh C, Chang HJ, Sung JM, Kim JY, Yang W, Shim J, et al. Prognostic estimation of advanced heart failure with low left ventricular ejection fraction and wide QRS interval. Korean Circ J. 2012;42:659–67.CrossRefPubMedPubMedCentral Oh C, Chang HJ, Sung JM, Kim JY, Yang W, Shim J, et al. Prognostic estimation of advanced heart failure with low left ventricular ejection fraction and wide QRS interval. Korean Circ J. 2012;42:659–67.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407–24.CrossRefPubMed Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol. 2009;54:1407–24.CrossRefPubMed
17.
Zurück zum Zitat Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and Management of Heart Failure Patients: cardiac magnetic resonance. Curr Heart Fail Rep. 2015;12:276–83.CrossRefPubMedPubMedCentral Gonzalez JA, Kramer CM. Role of imaging techniques for diagnosis, prognosis and Management of Heart Failure Patients: cardiac magnetic resonance. Curr Heart Fail Rep. 2015;12:276–83.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54–9.CrossRefPubMed McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54–9.CrossRefPubMed
19.
Zurück zum Zitat Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Udompunturak S. Late gadolinium enhancement from cardiac magnetic resonance in ischemic and non-ischemic cardiomyopathy. J Med Assoc Thail. 2011;94(Suppl 1):S33–8. Krittayaphong R, Boonyasirinant T, Saiviroonporn P, Udompunturak S. Late gadolinium enhancement from cardiac magnetic resonance in ischemic and non-ischemic cardiomyopathy. J Med Assoc Thail. 2011;94(Suppl 1):S33–8.
20.
Zurück zum Zitat Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7:250–8.CrossRefPubMed Kuruvilla S, Adenaw N, Katwal AB, Lipinski MJ, Kramer CM, Salerno M. Late gadolinium enhancement on cardiac magnetic resonance predicts adverse cardiovascular outcomes in nonischemic cardiomyopathy: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 2014;7:250–8.CrossRefPubMed
21.
Zurück zum Zitat Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908.CrossRefPubMed Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA. 2013;309:896–908.CrossRefPubMed
22.
Zurück zum Zitat Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H, et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97:727–32.CrossRefPubMed Lehrke S, Lossnitzer D, Schob M, Steen H, Merten C, Kemmling H, et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart. 2011;97:727–32.CrossRefPubMed
23.
Zurück zum Zitat Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–21.CrossRefPubMedPubMedCentral Wu KC, Weiss RG, Thiemann DR, Kitagawa K, Schmidt A, Dalal D, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–21.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Buss SJ, Breuninger K, Lehrke S, Voss A, Galuschky C, Lossnitzer D, et al. Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2015;16:307–15.CrossRefPubMed Buss SJ, Breuninger K, Lehrke S, Voss A, Galuschky C, Lossnitzer D, et al. Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2015;16:307–15.CrossRefPubMed
25.
Zurück zum Zitat Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/international society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–2.CrossRefPubMed Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O'Connell J, et al. Report of the 1995 World Health Organization/international society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996;93:841–2.CrossRefPubMed
26.
Zurück zum Zitat Liu T, Ma X, Liu W, Ling S, Zhao L, Xu L, et al. Late gadolinium enhancement amount as an independent risk factor for the incidence of adverse cardiovascular events in patients with stage C or D heart failure. Front Physiol. 2016;7:484.PubMedPubMedCentral Liu T, Ma X, Liu W, Ling S, Zhao L, Xu L, et al. Late gadolinium enhancement amount as an independent risk factor for the incidence of adverse cardiovascular events in patients with stage C or D heart failure. Front Physiol. 2016;7:484.PubMedPubMedCentral
27.
Zurück zum Zitat Maron MS. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters. JACC Cardiovasc Imaging. 2013;6:597–9.CrossRefPubMed Maron MS. Contrast-enhanced CMR in HCM: what lies behind the bright light of LGE and why it now matters. JACC Cardiovasc Imaging. 2013;6:597–9.CrossRefPubMed
28.
Zurück zum Zitat Lee JM, Rhee TM, Hahn JY, Hwang D, Park J, Park KW, et al. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: patient-level pooled analysis of Korean multicenter in-stent restenosis registry. Int J Cardiol. 2017;230:181–90.CrossRefPubMed Lee JM, Rhee TM, Hahn JY, Hwang D, Park J, Park KW, et al. Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: patient-level pooled analysis of Korean multicenter in-stent restenosis registry. Int J Cardiol. 2017;230:181–90.CrossRefPubMed
29.
Zurück zum Zitat MacIver DH, Adeniran I, Zhang H. Left ventricular ejection fraction is determined by both global myocardial strain and wall thickness. IJC Heart & Vasculature. 2015;7:113–8.CrossRef MacIver DH, Adeniran I, Zhang H. Left ventricular ejection fraction is determined by both global myocardial strain and wall thickness. IJC Heart & Vasculature. 2015;7:113–8.CrossRef
30.
Zurück zum Zitat Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–85.CrossRefPubMed Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–85.CrossRefPubMed
Metadaten
Titel
Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction
verfasst von
Seung-Hoon Pi
Sung Mok Kim
Jin-Oh Choi
Eun Kyoung Kim
Sung-A Chang
Yeon Hyeon Choe
Sang-Chol Lee
Eun-Seok Jeon
Publikationsdatum
01.12.2018
Verlag
BioMed Central
Erschienen in
Journal of Cardiovascular Magnetic Resonance / Ausgabe 1/2018
Elektronische ISSN: 1532-429X
DOI
https://doi.org/10.1186/s12968-018-0466-7

Weitere Artikel der Ausgabe 1/2018

Journal of Cardiovascular Magnetic Resonance 1/2018 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.